Linked Life Data

1642186

Source:http://linkedlifedata.com/resource/pubmed/id/1642186

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1642186rdf:typepubmed:Citationlld:pubmed
pubmed-article:1642186lifeskim:mentionsumls-concept:C0376298lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0240951lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0679729lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0018802lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0232804lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0014025lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C2709058lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:1642186lifeskim:mentionsumls-concept:C1709269lld:lifeskim
pubmed-article:1642186pubmed:issue4lld:pubmed
pubmed-article:1642186pubmed:dateCreated1992-9-3lld:pubmed
pubmed-article:1642186pubmed:abstractTextThe effect on renal function of long-term treatment with either enalapril (n = 123) or placebo (n = 120) in addition to conventional therapy was studied in a randomized trial in patients with severe congestive heart failure (New York Heart Association functional class IV; the Cooperative North Scandinavian Enalapril Survival Study). Enalapril was administered in a dose of 2.5 to 40 mg/day. The analysis was restricted to the first 6 months of treatment. There was an average initial increase of 10 to 15% (10 to 20 mumol/liter) irrespective of baseline serum creatinine within the first 3 weeks of enalapril treatment, whereafter mean serum creatinine remained on a similar level during the first 6 months. Enalapril was well-tolerated by most patients, and serum creatinine was reduced in 24%. Serum creatinine increased by greater than 100% in 13 patients (11%) in the enalapril group (mainly as a consequence of intercurrent disease or severe hypotension, and usually transiently) and in 4 (3%) in the placebo group. The maximal increase in serum creatinine in the enalapril group was inversely correlated to the diastolic blood pressure (p = 0.008) at baseline and to the mean diastolic and systolic blood pressures measured at the time of the maximal increase in serum creatinine (p = 0.0001). According to multivariate regression analysis, the maximal increase in serum creatinine was also slightly influenced by the dose of furosemide taken. The development of hypotension emerged as the strongest factor explaining an abnormal increase in serum creatinine.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:1642186pubmed:languageenglld:pubmed
pubmed-article:1642186pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1642186pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1642186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1642186pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1642186pubmed:statusMEDLINElld:pubmed
pubmed-article:1642186pubmed:monthAuglld:pubmed
pubmed-article:1642186pubmed:issn0002-9149lld:pubmed
pubmed-article:1642186pubmed:authorpubmed-author:SwedbergKKlld:pubmed
pubmed-article:1642186pubmed:authorpubmed-author:KjekshusJJlld:pubmed
pubmed-article:1642186pubmed:authorpubmed-author:LjungmanSSlld:pubmed
pubmed-article:1642186pubmed:issnTypePrintlld:pubmed
pubmed-article:1642186pubmed:day15lld:pubmed
pubmed-article:1642186pubmed:volume70lld:pubmed
pubmed-article:1642186pubmed:ownerNLMlld:pubmed
pubmed-article:1642186pubmed:authorsCompleteYlld:pubmed
pubmed-article:1642186pubmed:pagination479-87lld:pubmed
pubmed-article:1642186pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:meshHeadingpubmed-meshheading:1642186-...lld:pubmed
pubmed-article:1642186pubmed:year1992lld:pubmed
pubmed-article:1642186pubmed:articleTitleRenal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial).lld:pubmed
pubmed-article:1642186pubmed:affiliationDepartment of Nephrology, Sahlgrenska Hospital, Gothenburg, Sweden.lld:pubmed
pubmed-article:1642186pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1642186pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1642186pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1642186pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1642186lld:pubmed